Pharsight

Sinuva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8109918 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(5 months from now)

US7951131 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(5 months from now)

US7951130 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(5 months from now)

US7662141 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(5 months from now)

US7713255 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(5 months from now)

US7951133 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(5 months from now)

US9585681 INTERSECT ENT INC Device and methods for treating paranasal sinus conditions
Apr, 2026

(2 years from now)

US7544192 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Nov, 2026

(3 years from now)

US8025635 INTERSECT ENT INC Device and methods for treating paranasal sinus conditions
Jun, 2027

(3 years from now)

US10357640 INTERSECT ENT INC Expandable devices and methods for treating a nasal or sinus condition
Oct, 2031

(8 years from now)

US8763222 INTERSECT ENT INC Methods and devices for crimping self-expanding devices
Feb, 2032

(8 years from now)

US10406332 INTERSECT ENT INC Systems, devices, and method for treating a sinus condition
Mar, 2034

(10 years from now)

US10232152 INTERSECT ENT INC Systems, devices, and method for treating a sinus condition
Nov, 2034

(11 years from now)

Sinuva is owned by Intersect Ent Inc.

Sinuva contains Mometasone Furoate.

Sinuva has a total of 13 drug patents out of which 0 drug patents have expired.

Sinuva was authorised for market use on 08 December, 2017.

Sinuva is available in implant;implantation dosage forms.

Sinuva can be used as treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant.

The generics of Sinuva are possible to be released after 24 November, 2034.

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 08 December, 2017

Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

SINUVA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic